| 摘要 |
PURPOSE: A non-nucleoside hepatitis C treating and preventing medicine is provided to exhibit high hepatitis C virus inhibition effect with few side effects. CONSTITUTION: A non-nucleoside hepatitis C treating and preventing medicine comprises a compound represented by formula 1, and its pharmacologically allowable salts. In formula 1, R1 ~ R5 are independently hydrogen or -R6-(CH2)n-R7, wherein R6 is O or NH, n is an integer between 1 and 3, and R7 is phenyl or the phenyl substituted with halogen. The compound is selected from the group consisting of 4-(4-benzyloxy-phenyl)-2-hydroxy-4-oxo-but-2-enoic acid, 4-[4-(4-chloro-benzyloxy)phenyl]-2-hydroxy-4-oxo-but-2-enoic acid, 4-(3-benzyloxy-phenyl)-2-hydroxy-4-oxo-but-2-enoic acid, 4-[3-(4-chloro-benzyl oxy)phenyl]-2-hydroxy-4-oxo-but-2-enoic acid, 4-(2-benzyloxy-phenyl)-2-hydroxy-4-oxo-but-2-enoic acid, 4-[2-(4-chloro-benzyl oxy)phenyl]-2-hydroxy-4-oxo-but-2-enoic acid, 4-(3-benzylamino-phenyl)-2-hydroxy-4-oxo-but-2-enoic acid, and 4-[3-(4-chloro-benzylamino)phenyl]-2-hydroxy-4-oxo-but-2-enoic acid.
|
